CONNEQT Health Expands U.S. Phase 2b Clinical Trial Contract to 45 Sites, Lifting Total Value to US$0.95 Million

Aditi Sarkar

09 November 2026 03:33 PM AEDT

CONNEQT Health Expands U.S. Phase 2b Clinical Trial Contract to 45 Sites, Lifting Total Value to US$0.95 Million

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

CONNEQT Health Limited (ASX:CQT) has disclosed that its wholly owned subsidiary, ATCOR Medical, Inc., has executed a contract amendment to expand a U.S. Phase 2b clinical trial from 30 to 45 investigational sites, increasing the total contract value to US$0.95 million (approximately A$1.36 million).

Key Points

Contract amendment expands the Phase 2b clinical trial from 30 to 45 investigational sites across the United States.
Incremental contract value of US$0.24 million (approximately A$0.34 million), lifting total contract value to US$0.95 million (approximately A$1.36 million).
15 additional SphygmoCor® XCEL systems and 30 additional Oscar 2 ABPM systems to be deployed for approximately seven months.
A non-refundable initiation fee of 30% of the amendment value is payable on execution, with remaining charges invoiced monthly.

Contract Amendment and Site Expansion Details

The amendment to the Phase 2b clinical trial contract was executed by ATCOR Medical, Inc., a wholly owned subsidiary of CONNEQT Health, with a privately owned U.S.-based biopharmaceutical company focused on developing therapies for the treatment of hypertension and other serious cardiovascular diseases. The expansion increases investigational sites from 30 to 45 across the United States and reflects the addition of a second study visit to the trial protocol. The amendment builds on the original contract first disclosed by the company on 28 October 2025.

Equipment Deployment and Services Provided

Under the amendment, CONNEQT Health will provide 15 additional SphygmoCor® XCEL systems and 30 additional Oscar 2 ABPM systems, with the additional equipment to be leased for approximately seven months. The company will also deliver equipment configuration, virtual operator training and certification, ongoing technical support, and data management services as part of the expanded scope. Unit pricing and all other terms, including confidentiality and termination provisions, remain unchanged from the original contract.

Financial Terms of the Amendment

The incremental value of the amendment is US$0.24 million (approximately A$0.34 million), inclusive of equipment leasing, operational support, and data management services. This represents a 33% increase on the original contract value of US$0.72 million, bringing the total contract value to US$0.95 million (approximately A$1.36 million). A non-refundable initiation fee of 30% of the amendment value is payable on execution, with equipment lease and other ongoing charges invoiced monthly. Revenue will be recognised progressively over the duration of the trial, according to the filing.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.